nodes	percent_of_prediction	percent_of_DWPC	metapath
Acamprosate—GRIN2A—Reelin signaling pathway—RAP1A—osteoporosis	0.00366	0.038	CbGpPWpGaD
Acamprosate—GRIN2B—Reelin signaling pathway—RAP1A—osteoporosis	0.00312	0.0323	CbGpPWpGaD
Acamprosate—GRIN1—EPHB-mediated forward signaling—ACTG1—osteoporosis	0.00282	0.0293	CbGpPWpGaD
Acamprosate—GRIN2B—EPHB-mediated forward signaling—ACTG1—osteoporosis	0.00275	0.0285	CbGpPWpGaD
Acamprosate—GRM5—G alpha (q) signalling events—MGLL—osteoporosis	0.00253	0.0262	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—MGLL—osteoporosis	0.00226	0.0235	CbGpPWpGaD
Acamprosate—GRIN2C—Alzheimers Disease—GAPDH—osteoporosis	0.00215	0.0223	CbGpPWpGaD
Acamprosate—GRIN2D—Alzheimers Disease—GAPDH—osteoporosis	0.002	0.0207	CbGpPWpGaD
Acamprosate—GRIN2A—Alzheimers Disease—GAPDH—osteoporosis	0.00164	0.017	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—PTH1R—osteoporosis	0.0016	0.0167	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—CALCR—osteoporosis	0.0016	0.0167	CbGpPWpGaD
Acamprosate—GRIN1—EPH-Ephrin signaling—ACTG1—osteoporosis	0.00145	0.0151	CbGpPWpGaD
Acamprosate—GRIN1—Alzheimers Disease—GAPDH—osteoporosis	0.00143	0.0149	CbGpPWpGaD
Acamprosate—GRIN2B—EPH-Ephrin signaling—ACTG1—osteoporosis	0.00141	0.0147	CbGpPWpGaD
Acamprosate—GRIN2B—Alzheimers Disease—GAPDH—osteoporosis	0.0014	0.0145	CbGpPWpGaD
Acamprosate—GABRB3—Orphan transporters—ANXA2—osteoporosis	0.00104	0.0108	CbGpPWpGaD
Acamprosate—GABRG2—Orphan transporters—ANXA2—osteoporosis	0.00102	0.0106	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—PTH1R—osteoporosis	0.000907	0.00941	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—CALCR—osteoporosis	0.000907	0.00941	CbGpPWpGaD
Acamprosate—GABRA1—Orphan transporters—ANXA2—osteoporosis	0.000891	0.00925	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—CAP1—osteoporosis	0.000873	0.00906	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—RAP1A—osteoporosis	0.000862	0.00895	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—CAP1—osteoporosis	0.000851	0.00883	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—PTH—osteoporosis	0.000843	0.00875	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—RAP1A—osteoporosis	0.000841	0.00872	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—GAPDH—osteoporosis	0.00083	0.00862	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—ALPL—osteoporosis	0.000828	0.00859	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—PTH1R—osteoporosis	0.000823	0.00855	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—CALCR—osteoporosis	0.000823	0.00855	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—CNR2—osteoporosis	0.000821	0.00852	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—ALPL—osteoporosis	0.000807	0.00838	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—WNT1—osteoporosis	0.000772	0.00801	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—BMP2—osteoporosis	0.000727	0.00755	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—MGLL—osteoporosis	0.00072	0.00748	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—BMP2—osteoporosis	0.000709	0.00736	CbGpPWpGaD
Acamprosate—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	0.000699	0.00726	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—PTHLH—osteoporosis	0.000698	0.00725	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000684	0.0071	CbGpPWpGaD
Acamprosate—GABRB3—GABA receptor activation—ADCY5—osteoporosis	0.000668	0.00693	CbGpPWpGaD
Acamprosate—GABRG2—GABA receptor activation—ADCY5—osteoporosis	0.000656	0.00681	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—MGLL—osteoporosis	0.000654	0.00679	CbGpPWpGaD
Acamprosate—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	0.00065	0.00675	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—CAP1—osteoporosis	0.000623	0.00647	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—CALCA—osteoporosis	0.000615	0.00638	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—CAP1—osteoporosis	0.000607	0.0063	CbGpPWpGaD
Acamprosate—GRIN2C—Alzheimers Disease—IL1B—osteoporosis	0.000603	0.00626	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—ESR2—osteoporosis	0.000576	0.00597	CbGpPWpGaD
Acamprosate—GABRA1—GABA receptor activation—ADCY5—osteoporosis	0.000573	0.00595	CbGpPWpGaD
Acamprosate—Arthralgia—Zoledronate—osteoporosis	0.000572	0.000633	CcSEcCtD
Acamprosate—Palpitations—Conjugated Estrogens—osteoporosis	0.000572	0.000633	CcSEcCtD
Acamprosate—Insomnia—Risedronate—osteoporosis	0.000571	0.000632	CcSEcCtD
Acamprosate—Anxiety—Zoledronate—osteoporosis	0.00057	0.000631	CcSEcCtD
Acamprosate—GABRB3—BDNF signaling pathway—RAP1A—osteoporosis	0.000569	0.0059	CbGpPWpGaD
Acamprosate—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000569	0.000629	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000568	0.000629	CcSEcCtD
Acamprosate—Paraesthesia—Risedronate—osteoporosis	0.000567	0.000628	CcSEcCtD
Acamprosate—Pruritus—Estropipate—osteoporosis	0.000565	0.000626	CcSEcCtD
Acamprosate—Discomfort—Zoledronate—osteoporosis	0.000565	0.000626	CcSEcCtD
Acamprosate—Asthenia—Alendronate—osteoporosis	0.000565	0.000625	CcSEcCtD
Acamprosate—Hypersensitivity—Ibandronate—osteoporosis	0.000565	0.000625	CcSEcCtD
Acamprosate—Cough—Conjugated Estrogens—osteoporosis	0.000565	0.000625	CcSEcCtD
Acamprosate—Dyspnoea—Risedronate—osteoporosis	0.000563	0.000623	CcSEcCtD
Acamprosate—Hypotension—Pamidronate—osteoporosis	0.000561	0.000621	CcSEcCtD
Acamprosate—GRIN2D—Alzheimers Disease—IL1B—osteoporosis	0.000561	0.00582	CbGpPWpGaD
Acamprosate—Convulsion—Conjugated Estrogens—osteoporosis	0.000561	0.00062	CcSEcCtD
Acamprosate—Dry mouth—Zoledronate—osteoporosis	0.00056	0.000619	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000559	0.000619	CcSEcCtD
Acamprosate—Pruritus—Alendronate—osteoporosis	0.000557	0.000616	CcSEcCtD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000556	0.00578	CbGpPWpGaD
Acamprosate—Dyspepsia—Risedronate—osteoporosis	0.000556	0.000615	CcSEcCtD
Acamprosate—Tinnitus—Estradiol—osteoporosis	0.000555	0.000614	CcSEcCtD
Acamprosate—Constipation—Ethinyl Estradiol—osteoporosis	0.000554	0.000613	CcSEcCtD
Acamprosate—Confusional state—Zoledronate—osteoporosis	0.000553	0.000612	CcSEcCtD
Acamprosate—Hypersensitivity—Calcitriol—osteoporosis	0.000553	0.000612	CcSEcCtD
Acamprosate—Chest pain—Conjugated Estrogens—osteoporosis	0.000551	0.00061	CcSEcCtD
Acamprosate—Myalgia—Conjugated Estrogens—osteoporosis	0.000551	0.00061	CcSEcCtD
Acamprosate—Arthralgia—Conjugated Estrogens—osteoporosis	0.000551	0.00061	CcSEcCtD
Acamprosate—Asthenia—Ibandronate—osteoporosis	0.00055	0.000609	CcSEcCtD
Acamprosate—Anxiety—Conjugated Estrogens—osteoporosis	0.000549	0.000608	CcSEcCtD
Acamprosate—Nausea—Etidronic acid—osteoporosis	0.000549	0.000607	CcSEcCtD
Acamprosate—Anaphylactic shock—Zoledronate—osteoporosis	0.000548	0.000607	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000547	0.000605	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000547	0.000605	CcSEcCtD
Acamprosate—Diarrhoea—Estropipate—osteoporosis	0.000547	0.000605	CcSEcCtD
Acamprosate—GRIN1—Axon guidance—TLN1—osteoporosis	0.000547	0.00567	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—ALPL—osteoporosis	0.000546	0.00567	CbGpPWpGaD
Acamprosate—Gastrointestinal disorder—Risedronate—osteoporosis	0.000545	0.000603	CcSEcCtD
Acamprosate—Infection—Zoledronate—osteoporosis	0.000545	0.000603	CcSEcCtD
Acamprosate—Insomnia—Pamidronate—osteoporosis	0.000543	0.000601	CcSEcCtD
Acamprosate—Pruritus—Ibandronate—osteoporosis	0.000542	0.0006	CcSEcCtD
Acamprosate—Pain—Risedronate—osteoporosis	0.00054	0.000598	CcSEcCtD
Acamprosate—Constipation—Risedronate—osteoporosis	0.00054	0.000598	CcSEcCtD
Acamprosate—Shock—Zoledronate—osteoporosis	0.00054	0.000597	CcSEcCtD
Acamprosate—GRIN1—Axon guidance—ACTG1—osteoporosis	0.000539	0.0056	CbGpPWpGaD
Acamprosate—Paraesthesia—Pamidronate—osteoporosis	0.000539	0.000597	CcSEcCtD
Acamprosate—Diarrhoea—Alendronate—osteoporosis	0.000539	0.000596	CcSEcCtD
Acamprosate—Asthenia—Calcitriol—osteoporosis	0.000538	0.000596	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—SOST—osteoporosis	0.000538	0.00558	CbGpPWpGaD
Acamprosate—Immune system disorder—Estradiol—osteoporosis	0.000537	0.000595	CcSEcCtD
Acamprosate—Thrombocytopenia—Zoledronate—osteoporosis	0.000537	0.000594	CcSEcCtD
Acamprosate—Dyspnoea—Pamidronate—osteoporosis	0.000535	0.000592	CcSEcCtD
Acamprosate—Tachycardia—Zoledronate—osteoporosis	0.000535	0.000592	CcSEcCtD
Acamprosate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	0.000534	0.00554	CbGpPWpGaD
Acamprosate—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000534	0.000591	CcSEcCtD
Acamprosate—Chills—Estradiol—osteoporosis	0.000534	0.000591	CcSEcCtD
Acamprosate—Somnolence—Pamidronate—osteoporosis	0.000534	0.000591	CcSEcCtD
Acamprosate—GRIN2B—Axon guidance—TLN1—osteoporosis	0.000533	0.00553	CbGpPWpGaD
Acamprosate—Skin disorder—Zoledronate—osteoporosis	0.000533	0.00059	CcSEcCtD
Acamprosate—Pruritus—Calcitriol—osteoporosis	0.000531	0.000587	CcSEcCtD
Acamprosate—Hyperhidrosis—Zoledronate—osteoporosis	0.00053	0.000587	CcSEcCtD
Acamprosate—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.00053	0.000586	CcSEcCtD
Acamprosate—Diarrhoea—Raloxifene—osteoporosis	0.00053	0.000586	CcSEcCtD
Acamprosate—Dyspepsia—Pamidronate—osteoporosis	0.000529	0.000585	CcSEcCtD
Acamprosate—Dizziness—Estropipate—osteoporosis	0.000528	0.000585	CcSEcCtD
Acamprosate—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000528	0.000584	CcSEcCtD
Acamprosate—GRIN2B—Axon guidance—ACTG1—osteoporosis	0.000526	0.00546	CbGpPWpGaD
Acamprosate—Alopecia—Estradiol—osteoporosis	0.000526	0.000582	CcSEcCtD
Acamprosate—GRIN2C—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000526	0.00546	CbGpPWpGaD
Acamprosate—Infection—Conjugated Estrogens—osteoporosis	0.000525	0.000581	CcSEcCtD
Acamprosate—Diarrhoea—Ibandronate—osteoporosis	0.000524	0.00058	CcSEcCtD
Acamprosate—Anorexia—Zoledronate—osteoporosis	0.000523	0.000579	CcSEcCtD
Acamprosate—Decreased appetite—Pamidronate—osteoporosis	0.000522	0.000578	CcSEcCtD
Acamprosate—Mental disorder—Estradiol—osteoporosis	0.000521	0.000577	CcSEcCtD
Acamprosate—Dizziness—Alendronate—osteoporosis	0.000521	0.000576	CcSEcCtD
Acamprosate—Shock—Conjugated Estrogens—osteoporosis	0.00052	0.000575	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000518	0.000574	CcSEcCtD
Acamprosate—Malnutrition—Estradiol—osteoporosis	0.000518	0.000573	CcSEcCtD
Acamprosate—Gastrointestinal pain—Risedronate—osteoporosis	0.000516	0.000572	CcSEcCtD
Acamprosate—Tachycardia—Conjugated Estrogens—osteoporosis	0.000515	0.00057	CcSEcCtD
Acamprosate—Urticaria—Ethinyl Estradiol—osteoporosis	0.000515	0.000569	CcSEcCtD
Acamprosate—Pain—Pamidronate—osteoporosis	0.000513	0.000568	CcSEcCtD
Acamprosate—Constipation—Pamidronate—osteoporosis	0.000513	0.000568	CcSEcCtD
Acamprosate—Diarrhoea—Calcitriol—osteoporosis	0.000513	0.000568	CcSEcCtD
Acamprosate—Skin disorder—Conjugated Estrogens—osteoporosis	0.000513	0.000568	CcSEcCtD
Acamprosate—Hypotension—Zoledronate—osteoporosis	0.000512	0.000567	CcSEcCtD
Acamprosate—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000512	0.000567	CcSEcCtD
Acamprosate—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000512	0.000567	CcSEcCtD
Acamprosate—Dizziness—Raloxifene—osteoporosis	0.000512	0.000567	CcSEcCtD
Acamprosate—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000511	0.000565	CcSEcCtD
Acamprosate—Flatulence—Estradiol—osteoporosis	0.00051	0.000565	CcSEcCtD
Acamprosate—Tension—Estradiol—osteoporosis	0.000508	0.000562	CcSEcCtD
Acamprosate—Vomiting—Estropipate—osteoporosis	0.000508	0.000562	CcSEcCtD
Acamprosate—Dysgeusia—Estradiol—osteoporosis	0.000507	0.000561	CcSEcCtD
Acamprosate—Dizziness—Ibandronate—osteoporosis	0.000507	0.000561	CcSEcCtD
Acamprosate—Rash—Estropipate—osteoporosis	0.000504	0.000558	CcSEcCtD
Acamprosate—Dermatitis—Estropipate—osteoporosis	0.000503	0.000557	CcSEcCtD
Acamprosate—Anorexia—Conjugated Estrogens—osteoporosis	0.000503	0.000557	CcSEcCtD
Acamprosate—Nervousness—Estradiol—osteoporosis	0.000503	0.000557	CcSEcCtD
Acamprosate—Urticaria—Risedronate—osteoporosis	0.000502	0.000555	CcSEcCtD
Acamprosate—Back pain—Estradiol—osteoporosis	0.000501	0.000554	CcSEcCtD
Acamprosate—Headache—Estropipate—osteoporosis	0.000501	0.000554	CcSEcCtD
Acamprosate—Vomiting—Alendronate—osteoporosis	0.0005	0.000554	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.0005	0.000553	CcSEcCtD
Acamprosate—Abdominal pain—Risedronate—osteoporosis	0.000499	0.000553	CcSEcCtD
Acamprosate—Body temperature increased—Risedronate—osteoporosis	0.000499	0.000553	CcSEcCtD
Acamprosate—Muscle spasms—Estradiol—osteoporosis	0.000498	0.000551	CcSEcCtD
Acamprosate—Rash—Alendronate—osteoporosis	0.000496	0.000549	CcSEcCtD
Acamprosate—Insomnia—Zoledronate—osteoporosis	0.000496	0.000549	CcSEcCtD
Acamprosate—Dermatitis—Alendronate—osteoporosis	0.000496	0.000549	CcSEcCtD
Acamprosate—Feeling abnormal—Pamidronate—osteoporosis	0.000495	0.000548	CcSEcCtD
Acamprosate—Hypotension—Conjugated Estrogens—osteoporosis	0.000493	0.000546	CcSEcCtD
Acamprosate—Headache—Alendronate—osteoporosis	0.000493	0.000546	CcSEcCtD
Acamprosate—Paraesthesia—Zoledronate—osteoporosis	0.000492	0.000545	CcSEcCtD
Acamprosate—Vomiting—Raloxifene—osteoporosis	0.000492	0.000545	CcSEcCtD
Acamprosate—Gastrointestinal pain—Pamidronate—osteoporosis	0.000491	0.000543	CcSEcCtD
Acamprosate—Dyspnoea—Zoledronate—osteoporosis	0.000489	0.000541	CcSEcCtD
Acamprosate—GRIN2D—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000489	0.00507	CbGpPWpGaD
Acamprosate—Rash—Raloxifene—osteoporosis	0.000488	0.00054	CcSEcCtD
Acamprosate—Dermatitis—Raloxifene—osteoporosis	0.000488	0.00054	CcSEcCtD
Acamprosate—Somnolence—Zoledronate—osteoporosis	0.000488	0.00054	CcSEcCtD
Acamprosate—Vomiting—Ibandronate—osteoporosis	0.000487	0.000539	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—CALCR—osteoporosis	0.000486	0.00505	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PTH1R—osteoporosis	0.000486	0.00505	CbGpPWpGaD
Acamprosate—Tremor—Estradiol—osteoporosis	0.000485	0.000537	CcSEcCtD
Acamprosate—Headache—Raloxifene—osteoporosis	0.000485	0.000537	CcSEcCtD
Acamprosate—Rash—Ibandronate—osteoporosis	0.000483	0.000535	CcSEcCtD
Acamprosate—Dermatitis—Ibandronate—osteoporosis	0.000483	0.000534	CcSEcCtD
Acamprosate—Dyspepsia—Zoledronate—osteoporosis	0.000483	0.000534	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000481	0.000532	CcSEcCtD
Acamprosate—Ill-defined disorder—Estradiol—osteoporosis	0.00048	0.000532	CcSEcCtD
Acamprosate—Headache—Ibandronate—osteoporosis	0.00048	0.000531	CcSEcCtD
Acamprosate—GABRB3—BDNF signaling pathway—BMP2—osteoporosis	0.00048	0.00498	CbGpPWpGaD
Acamprosate—Insomnia—Conjugated Estrogens—osteoporosis	0.000478	0.000529	CcSEcCtD
Acamprosate—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000477	0.000528	CcSEcCtD
Acamprosate—Vomiting—Calcitriol—osteoporosis	0.000477	0.000528	CcSEcCtD
Acamprosate—Decreased appetite—Zoledronate—osteoporosis	0.000477	0.000528	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—PTH—osteoporosis	0.000476	0.00494	CbGpPWpGaD
Acamprosate—Agitation—Estradiol—osteoporosis	0.000476	0.000527	CcSEcCtD
Acamprosate—Nausea—Estropipate—osteoporosis	0.000475	0.000525	CcSEcCtD
Acamprosate—Abdominal pain—Pamidronate—osteoporosis	0.000475	0.000525	CcSEcCtD
Acamprosate—Body temperature increased—Pamidronate—osteoporosis	0.000475	0.000525	CcSEcCtD
Acamprosate—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000474	0.000525	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000473	0.000524	CcSEcCtD
Acamprosate—Angioedema—Estradiol—osteoporosis	0.000473	0.000524	CcSEcCtD
Acamprosate—Rash—Calcitriol—osteoporosis	0.000473	0.000523	CcSEcCtD
Acamprosate—Dermatitis—Calcitriol—osteoporosis	0.000473	0.000523	CcSEcCtD
Acamprosate—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000471	0.000521	CcSEcCtD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—GAPDH—osteoporosis	0.00047	0.00488	CbGpPWpGaD
Acamprosate—Headache—Calcitriol—osteoporosis	0.00047	0.00052	CcSEcCtD
Acamprosate—Somnolence—Conjugated Estrogens—osteoporosis	0.000469	0.00052	CcSEcCtD
Acamprosate—Constipation—Zoledronate—osteoporosis	0.000469	0.000519	CcSEcCtD
Acamprosate—Pain—Zoledronate—osteoporosis	0.000469	0.000519	CcSEcCtD
Acamprosate—Nausea—Alendronate—osteoporosis	0.000468	0.000517	CcSEcCtD
Acamprosate—Malaise—Estradiol—osteoporosis	0.000467	0.000517	CcSEcCtD
Acamprosate—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	0.000466	0.00483	CbGpPWpGaD
Acamprosate—Hypersensitivity—Risedronate—osteoporosis	0.000465	0.000515	CcSEcCtD
Acamprosate—Vertigo—Estradiol—osteoporosis	0.000465	0.000515	CcSEcCtD
Acamprosate—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000465	0.000514	CcSEcCtD
Acamprosate—Asthenia—Ethinyl Estradiol—osteoporosis	0.000465	0.000514	CcSEcCtD
Acamprosate—Syncope—Estradiol—osteoporosis	0.000464	0.000514	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—CNR2—osteoporosis	0.000464	0.00482	CbGpPWpGaD
Acamprosate—GRIN2A—Alzheimers Disease—IL1B—osteoporosis	0.000461	0.00478	CbGpPWpGaD
Acamprosate—Nausea—Raloxifene—osteoporosis	0.00046	0.000509	CcSEcCtD
Acamprosate—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000459	0.000508	CcSEcCtD
Acamprosate—Pruritus—Ethinyl Estradiol—osteoporosis	0.000458	0.000507	CcSEcCtD
Acamprosate—Palpitations—Estradiol—osteoporosis	0.000458	0.000506	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—LEP—osteoporosis	0.000457	0.00474	CbGpPWpGaD
Acamprosate—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000456	0.000505	CcSEcCtD
Acamprosate—Nausea—Ibandronate—osteoporosis	0.000455	0.000504	CcSEcCtD
Acamprosate—Loss of consciousness—Estradiol—osteoporosis	0.000455	0.000504	CcSEcCtD
Acamprosate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	0.000454	0.00471	CbGpPWpGaD
Acamprosate—Asthenia—Risedronate—osteoporosis	0.000453	0.000501	CcSEcCtD
Acamprosate—Feeling abnormal—Zoledronate—osteoporosis	0.000452	0.0005	CcSEcCtD
Acamprosate—Cough—Estradiol—osteoporosis	0.000452	0.0005	CcSEcCtD
Acamprosate—Pain—Conjugated Estrogens—osteoporosis	0.000452	0.0005	CcSEcCtD
Acamprosate—Constipation—Conjugated Estrogens—osteoporosis	0.000452	0.0005	CcSEcCtD
Acamprosate—Gastrointestinal pain—Zoledronate—osteoporosis	0.000448	0.000496	CcSEcCtD
Acamprosate—Hypertension—Estradiol—osteoporosis	0.000447	0.000495	CcSEcCtD
Acamprosate—Pruritus—Risedronate—osteoporosis	0.000447	0.000495	CcSEcCtD
Acamprosate—Nausea—Calcitriol—osteoporosis	0.000446	0.000493	CcSEcCtD
Acamprosate—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000443	0.00049	CcSEcCtD
Acamprosate—Hypersensitivity—Pamidronate—osteoporosis	0.000442	0.00049	CcSEcCtD
Acamprosate—Chest pain—Estradiol—osteoporosis	0.000441	0.000488	CcSEcCtD
Acamprosate—Arthralgia—Estradiol—osteoporosis	0.000441	0.000488	CcSEcCtD
Acamprosate—Myalgia—Estradiol—osteoporosis	0.000441	0.000488	CcSEcCtD
Acamprosate—GRIN1—BDNF signaling pathway—SPP1—osteoporosis	0.00044	0.00457	CbGpPWpGaD
Acamprosate—Anxiety—Estradiol—osteoporosis	0.000439	0.000486	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000438	0.000485	CcSEcCtD
Acamprosate—GRIN2C—Alzheimers Disease—TNF—osteoporosis	0.000438	0.00454	CbGpPWpGaD
Acamprosate—Urticaria—Zoledronate—osteoporosis	0.000436	0.000482	CcSEcCtD
Acamprosate—Discomfort—Estradiol—osteoporosis	0.000436	0.000482	CcSEcCtD
Acamprosate—Body temperature increased—Zoledronate—osteoporosis	0.000434	0.00048	CcSEcCtD
Acamprosate—Abdominal pain—Zoledronate—osteoporosis	0.000434	0.00048	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—PTH—osteoporosis	0.000433	0.00449	CbGpPWpGaD
Acamprosate—Diarrhoea—Risedronate—osteoporosis	0.000432	0.000478	CcSEcCtD
Acamprosate—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000432	0.000478	CcSEcCtD
Acamprosate—Dry mouth—Estradiol—osteoporosis	0.000431	0.000477	CcSEcCtD
Acamprosate—Asthenia—Pamidronate—osteoporosis	0.000431	0.000477	CcSEcCtD
Acamprosate—GRIN2B—BDNF signaling pathway—SPP1—osteoporosis	0.000429	0.00446	CbGpPWpGaD
Acamprosate—Dizziness—Ethinyl Estradiol—osteoporosis	0.000428	0.000474	CcSEcCtD
Acamprosate—Confusional state—Estradiol—osteoporosis	0.000426	0.000472	CcSEcCtD
Acamprosate—Pruritus—Pamidronate—osteoporosis	0.000425	0.00047	CcSEcCtD
Acamprosate—Anaphylactic shock—Estradiol—osteoporosis	0.000423	0.000468	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—CNR2—osteoporosis	0.000421	0.00437	CbGpPWpGaD
Acamprosate—Infection—Estradiol—osteoporosis	0.00042	0.000465	CcSEcCtD
Acamprosate—Urticaria—Conjugated Estrogens—osteoporosis	0.00042	0.000464	CcSEcCtD
Acamprosate—Dizziness—Risedronate—osteoporosis	0.000418	0.000462	CcSEcCtD
Acamprosate—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000417	0.000462	CcSEcCtD
Acamprosate—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000417	0.000462	CcSEcCtD
Acamprosate—Shock—Estradiol—osteoporosis	0.000416	0.00046	CcSEcCtD
Acamprosate—Tachycardia—Estradiol—osteoporosis	0.000412	0.000456	CcSEcCtD
Acamprosate—Vomiting—Ethinyl Estradiol—osteoporosis	0.000412	0.000456	CcSEcCtD
Acamprosate—Diarrhoea—Pamidronate—osteoporosis	0.000411	0.000455	CcSEcCtD
Acamprosate—Skin disorder—Estradiol—osteoporosis	0.000411	0.000454	CcSEcCtD
Acamprosate—Hyperhidrosis—Estradiol—osteoporosis	0.000409	0.000452	CcSEcCtD
Acamprosate—Rash—Ethinyl Estradiol—osteoporosis	0.000408	0.000452	CcSEcCtD
Acamprosate—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000408	0.000452	CcSEcCtD
Acamprosate—GRIN2D—Alzheimers Disease—TNF—osteoporosis	0.000407	0.00422	CbGpPWpGaD
Acamprosate—Headache—Ethinyl Estradiol—osteoporosis	0.000406	0.000449	CcSEcCtD
Acamprosate—Hypersensitivity—Zoledronate—osteoporosis	0.000404	0.000447	CcSEcCtD
Acamprosate—GRIN2C—Neuronal System—ADCY5—osteoporosis	0.000403	0.00418	CbGpPWpGaD
Acamprosate—GRIN1—Alzheimers Disease—IL1B—osteoporosis	0.000402	0.00417	CbGpPWpGaD
Acamprosate—Vomiting—Risedronate—osteoporosis	0.000402	0.000444	CcSEcCtD
Acamprosate—GRIN2A—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000401	0.00417	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—IRS2—osteoporosis	0.000398	0.00413	CbGpPWpGaD
Acamprosate—Rash—Risedronate—osteoporosis	0.000398	0.000441	CcSEcCtD
Acamprosate—Dermatitis—Risedronate—osteoporosis	0.000398	0.00044	CcSEcCtD
Acamprosate—Dizziness—Pamidronate—osteoporosis	0.000397	0.000439	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—WNT1—osteoporosis	0.000396	0.00411	CbGpPWpGaD
Acamprosate—Headache—Risedronate—osteoporosis	0.000396	0.000438	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—PTHLH—osteoporosis	0.000395	0.0041	CbGpPWpGaD
Acamprosate—Asthenia—Zoledronate—osteoporosis	0.000393	0.000435	CcSEcCtD
Acamprosate—GRIN2B—Alzheimers Disease—IL1B—osteoporosis	0.000392	0.00406	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—TLN1—osteoporosis	0.00039	0.00405	CbGpPWpGaD
Acamprosate—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000389	0.000431	CcSEcCtD
Acamprosate—GRIN2B—BDNF signaling pathway—IRS2—osteoporosis	0.000388	0.00403	CbGpPWpGaD
Acamprosate—Pruritus—Zoledronate—osteoporosis	0.000388	0.000429	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—MGLL—osteoporosis	0.000386	0.00401	CbGpPWpGaD
Acamprosate—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000385	0.000426	CcSEcCtD
Acamprosate—GRIN1—Developmental Biology—ACTG1—osteoporosis	0.000385	0.00399	CbGpPWpGaD
Acamprosate—Nausea—Ethinyl Estradiol—osteoporosis	0.000385	0.000426	CcSEcCtD
Acamprosate—Insomnia—Estradiol—osteoporosis	0.000382	0.000423	CcSEcCtD
Acamprosate—Vomiting—Pamidronate—osteoporosis	0.000382	0.000422	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—TLN1—osteoporosis	0.00038	0.00395	CbGpPWpGaD
Acamprosate—Paraesthesia—Estradiol—osteoporosis	0.00038	0.00042	CcSEcCtD
Acamprosate—Asthenia—Conjugated Estrogens—osteoporosis	0.000379	0.000419	CcSEcCtD
Acamprosate—Rash—Pamidronate—osteoporosis	0.000379	0.000419	CcSEcCtD
Acamprosate—Dermatitis—Pamidronate—osteoporosis	0.000378	0.000419	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—LRP5—osteoporosis	0.000377	0.00391	CbGpPWpGaD
Acamprosate—Dyspnoea—Estradiol—osteoporosis	0.000377	0.000417	CcSEcCtD
Acamprosate—Headache—Pamidronate—osteoporosis	0.000376	0.000416	CcSEcCtD
Acamprosate—Somnolence—Estradiol—osteoporosis	0.000376	0.000416	CcSEcCtD
Acamprosate—Diarrhoea—Zoledronate—osteoporosis	0.000375	0.000415	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—ACTG1—osteoporosis	0.000375	0.00389	CbGpPWpGaD
Acamprosate—Nausea—Risedronate—osteoporosis	0.000375	0.000415	CcSEcCtD
Acamprosate—GRIN2D—Neuronal System—ADCY5—osteoporosis	0.000374	0.00389	CbGpPWpGaD
Acamprosate—Pruritus—Conjugated Estrogens—osteoporosis	0.000374	0.000413	CcSEcCtD
Acamprosate—Dyspepsia—Estradiol—osteoporosis	0.000372	0.000412	CcSEcCtD
Acamprosate—Decreased appetite—Estradiol—osteoporosis	0.000367	0.000407	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Estradiol—osteoporosis	0.000365	0.000404	CcSEcCtD
Acamprosate—Dizziness—Zoledronate—osteoporosis	0.000363	0.000401	CcSEcCtD
Acamprosate—Constipation—Estradiol—osteoporosis	0.000361	0.0004	CcSEcCtD
Acamprosate—Pain—Estradiol—osteoporosis	0.000361	0.0004	CcSEcCtD
Acamprosate—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000361	0.0004	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—LRP6—osteoporosis	0.000361	0.00374	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—PTHLH—osteoporosis	0.000358	0.00372	CbGpPWpGaD
Acamprosate—Nausea—Pamidronate—osteoporosis	0.000357	0.000395	CcSEcCtD
Acamprosate—GRIN1—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.00035	0.00363	CbGpPWpGaD
Acamprosate—Dizziness—Conjugated Estrogens—osteoporosis	0.000349	0.000386	CcSEcCtD
Acamprosate—Vomiting—Zoledronate—osteoporosis	0.000349	0.000386	CcSEcCtD
Acamprosate—Feeling abnormal—Estradiol—osteoporosis	0.000348	0.000385	CcSEcCtD
Acamprosate—GRIN1—BDNF signaling pathway—IRS1—osteoporosis	0.000348	0.00361	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—CALCA—osteoporosis	0.000347	0.00361	CbGpPWpGaD
Acamprosate—Rash—Zoledronate—osteoporosis	0.000346	0.000383	CcSEcCtD
Acamprosate—Gastrointestinal pain—Estradiol—osteoporosis	0.000346	0.000382	CcSEcCtD
Acamprosate—Dermatitis—Zoledronate—osteoporosis	0.000345	0.000382	CcSEcCtD
Acamprosate—Headache—Zoledronate—osteoporosis	0.000344	0.00038	CcSEcCtD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000341	0.00354	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—IRS1—osteoporosis	0.000339	0.00352	CbGpPWpGaD
Acamprosate—Vomiting—Conjugated Estrogens—osteoporosis	0.000336	0.000372	CcSEcCtD
Acamprosate—Urticaria—Estradiol—osteoporosis	0.000336	0.000372	CcSEcCtD
Acamprosate—GRIN2A—Alzheimers Disease—TNF—osteoporosis	0.000334	0.00347	CbGpPWpGaD
Acamprosate—Abdominal pain—Estradiol—osteoporosis	0.000334	0.00037	CcSEcCtD
Acamprosate—Body temperature increased—Estradiol—osteoporosis	0.000334	0.00037	CcSEcCtD
Acamprosate—Rash—Conjugated Estrogens—osteoporosis	0.000333	0.000368	CcSEcCtD
Acamprosate—Dermatitis—Conjugated Estrogens—osteoporosis	0.000333	0.000368	CcSEcCtD
Acamprosate—Headache—Conjugated Estrogens—osteoporosis	0.000331	0.000366	CcSEcCtD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—ESR2—osteoporosis	0.000326	0.00338	CbGpPWpGaD
Acamprosate—Nausea—Zoledronate—osteoporosis	0.000326	0.00036	CcSEcCtD
Acamprosate—GRM5—GPCR ligand binding—POMC—osteoporosis	0.000322	0.00334	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—CALCA—osteoporosis	0.000316	0.00327	CbGpPWpGaD
Acamprosate—Nausea—Conjugated Estrogens—osteoporosis	0.000314	0.000347	CcSEcCtD
Acamprosate—Hypersensitivity—Estradiol—osteoporosis	0.000311	0.000345	CcSEcCtD
Acamprosate—GRIN2A—Neuronal System—ADCY5—osteoporosis	0.000307	0.00319	CbGpPWpGaD
Acamprosate—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	0.000307	0.00319	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—IL6R—osteoporosis	0.000306	0.00318	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TLN1—osteoporosis	0.000305	0.00316	CbGpPWpGaD
Acamprosate—Asthenia—Estradiol—osteoporosis	0.000303	0.000336	CcSEcCtD
Acamprosate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	0.000302	0.00313	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—WNT1—osteoporosis	0.0003	0.00311	CbGpPWpGaD
Acamprosate—Pruritus—Estradiol—osteoporosis	0.000299	0.000331	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—WNT1—osteoporosis	0.000292	0.00303	CbGpPWpGaD
Acamprosate—GRIN1—Alzheimers Disease—TNF—osteoporosis	0.000291	0.00303	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—IL1B—osteoporosis	0.000291	0.00302	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—SPP1—osteoporosis	0.000291	0.00302	CbGpPWpGaD
Acamprosate—Diarrhoea—Estradiol—osteoporosis	0.000289	0.00032	CcSEcCtD
Acamprosate—GRIN2B—Alzheimers Disease—TNF—osteoporosis	0.000284	0.00295	CbGpPWpGaD
Acamprosate—Dizziness—Estradiol—osteoporosis	0.000279	0.000309	CcSEcCtD
Acamprosate—Vomiting—Estradiol—osteoporosis	0.000269	0.000297	CcSEcCtD
Acamprosate—GRIN1—Neuronal System—ADCY5—osteoporosis	0.000268	0.00278	CbGpPWpGaD
Acamprosate—Rash—Estradiol—osteoporosis	0.000266	0.000295	CcSEcCtD
Acamprosate—Dermatitis—Estradiol—osteoporosis	0.000266	0.000295	CcSEcCtD
Acamprosate—Headache—Estradiol—osteoporosis	0.000265	0.000293	CcSEcCtD
Acamprosate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	0.000264	0.00274	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—IRS2—osteoporosis	0.000263	0.00273	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—P4HB—osteoporosis	0.000263	0.00273	CbGpPWpGaD
Acamprosate—GRIN2B—Neuronal System—ADCY5—osteoporosis	0.000261	0.00271	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—ADCY5—osteoporosis	0.000257	0.00266	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PTH—osteoporosis	0.000255	0.00265	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000254	0.00263	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—RAP1A—osteoporosis	0.000251	0.00261	CbGpPWpGaD
Acamprosate—Nausea—Estradiol—osteoporosis	0.000251	0.000278	CcSEcCtD
Acamprosate—GABRG2—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000249	0.00258	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CNR2—osteoporosis	0.000249	0.00258	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	0.000248	0.00257	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—ADCY5—osteoporosis	0.000247	0.00257	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—NFATC1—osteoporosis	0.000245	0.00254	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—DKK1—osteoporosis	0.000243	0.00252	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—WNT1—osteoporosis	0.000234	0.00243	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—IL1B—osteoporosis	0.000233	0.00242	CbGpPWpGaD
Acamprosate—GABRB3—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000231	0.0024	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—IRS1—osteoporosis	0.000229	0.00238	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—FGA—osteoporosis	0.000228	0.00236	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—MYC—osteoporosis	0.000227	0.00236	CbGpPWpGaD
Acamprosate—GABRG2—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000227	0.00235	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—TGFB1—osteoporosis	0.000226	0.00235	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—ADCY5—osteoporosis	0.000224	0.00233	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000218	0.00226	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PTHLH—osteoporosis	0.000212	0.0022	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—BMP2—osteoporosis	0.000212	0.0022	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—TNF—osteoporosis	0.000211	0.00219	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—FGB—osteoporosis	0.000207	0.00215	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PSMA2—osteoporosis	0.0002	0.00208	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PSMA5—osteoporosis	0.0002	0.00208	CbGpPWpGaD
Acamprosate—GABRA1—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000198	0.00206	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CALCA—osteoporosis	0.000186	0.00193	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—POMC—osteoporosis	0.000182	0.00189	CbGpPWpGaD
Acamprosate—GABRB3—Neuronal System—ADCY5—osteoporosis	0.000177	0.00184	CbGpPWpGaD
Acamprosate—GABRG2—Neuronal System—ADCY5—osteoporosis	0.000174	0.0018	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—IL6R—osteoporosis	0.000173	0.0018	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—IL6R—osteoporosis	0.000171	0.00177	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—IL6—osteoporosis	0.000171	0.00177	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—KL—osteoporosis	0.000169	0.00176	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—TNF—osteoporosis	0.000169	0.00176	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—IL6R—osteoporosis	0.000166	0.00173	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—POMC—osteoporosis	0.000165	0.00171	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—IL6R—osteoporosis	0.000161	0.00167	CbGpPWpGaD
Acamprosate—GABRA1—Neuronal System—ADCY5—osteoporosis	0.000152	0.00158	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—LEP—osteoporosis	0.000145	0.00151	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—LEP—osteoporosis	0.000142	0.00147	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—IL6—osteoporosis	0.000136	0.00142	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—ADCY5—osteoporosis	0.000133	0.00138	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—IL1B—osteoporosis	0.000132	0.00137	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—SPP1—osteoporosis	0.000128	0.00133	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—IL6R—osteoporosis	0.000122	0.00126	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—IL6R—osteoporosis	0.000119	0.00123	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—IRS2—osteoporosis	0.000116	0.0012	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—LEP—osteoporosis	0.000114	0.00118	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—ESR1—osteoporosis	0.000108	0.00112	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—IRS1—osteoporosis	0.000101	0.00105	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—POMC—osteoporosis	9.75e-05	0.00101	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—TNF—osteoporosis	9.58e-05	0.000994	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—ADCY5—osteoporosis	9.51e-05	0.000987	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—IL6R—osteoporosis	9.51e-05	0.000987	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—IGF1—osteoporosis	9.38e-05	0.000974	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—ADCY5—osteoporosis	9.34e-05	0.00097	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—ADCY5—osteoporosis	8.17e-05	0.000847	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—IL6—osteoporosis	7.73e-05	0.000802	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—IL6—osteoporosis	7.61e-05	0.000789	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—IL6—osteoporosis	7.41e-05	0.00077	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—TGFB1—osteoporosis	7.2e-05	0.000748	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—IL6—osteoporosis	7.17e-05	0.000744	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—TGFB1—osteoporosis	7.02e-05	0.000729	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—TNF—osteoporosis	6.73e-05	0.000698	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—TNF—osteoporosis	6.56e-05	0.00068	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—MYC—osteoporosis	5.64e-05	0.000585	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TGFB1—osteoporosis	5.62e-05	0.000584	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—IL6—osteoporosis	5.43e-05	0.000563	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—IL6—osteoporosis	5.29e-05	0.000549	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—IL6—osteoporosis	4.24e-05	0.00044	CbGpPWpGaD
